<SEC-DOCUMENT>0001140361-23-026106.txt : 20230522
<SEC-HEADER>0001140361-23-026106.hdr.sgml : 20230522
<ACCEPTANCE-DATETIME>20230522213050
ACCESSION NUMBER:		0001140361-23-026106
CONFORMED SUBMISSION TYPE:	144
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20230522
DATE AS OF CHANGE:		20230522

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Roivant Sciences Ltd.
		CENTRAL INDEX KEY:			0001635088
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				981173944
		STATE OF INCORPORATION:			D0
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		144
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	001-40782
		FILM NUMBER:		23946367

	BUSINESS ADDRESS:	
		STREET 1:		CLARENDON HOUSE, 2 CHURCH STREET
		CITY:			HAMILTON HM11
		STATE:			D0
		ZIP:			HM11
		BUSINESS PHONE:		441-295-5950

	MAIL ADDRESS:	
		STREET 1:		CLARENDON HOUSE
		STREET 2:		2 CHURCH STREET
		CITY:			HAMILTON
		STATE:			D0
		ZIP:			HM11

REPORTING-OWNER:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Gline Matthew
		CENTRAL INDEX KEY:			0001750094

	FILING VALUES:
		FORM TYPE:		144

	MAIL ADDRESS:	
		STREET 1:		C/O UROVANT SCIENCES, INC.
		STREET 2:		5151 CALIFORNIA AVENUE, SUITE 250
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92617
</SEC-HEADER>
<DOCUMENT>
<TYPE>144
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/ownership" xmlns:com="http://www.sec.gov/edgar/common">
<headerData>
<submissionType>144</submissionType>
<filerInfo>
<filer>
<filerCredentials>
<cik>0001750094</cik>
<ccc>XXXXXXXX</ccc>
</filerCredentials>
</filer>
<liveTestFlag>LIVE</liveTestFlag>



</filerInfo>
</headerData>
<formData>
<issuerInfo>
<issuerCik>0001635088</issuerCik>
<issuerName>Roivant Sciences Ltd.</issuerName>
<secFileNumber>001-40782</secFileNumber>
<issuerAddress>
<com:street1>7th Floor</com:street1>
<com:street2>50 Broadway</com:street2>
<com:city>London</com:city>
<com:stateOrCountry>X0</com:stateOrCountry>
<com:zipCode>SW1H 0DB</com:zipCode>
</issuerAddress>
<issuerContactPhone>442074003347</issuerContactPhone>
<nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>Gline Matthew</nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
<relationshipsToIssuer>
<relationshipToIssuer>Director CEO</relationshipToIssuer>
</relationshipsToIssuer>
</issuerInfo>
<securitiesInformation>
<securitiesClassTitle>Common shares, $0.0000000341740141 par value per share Common Shares</securitiesClassTitle>
<brokerOrMarketmakerDetails>
<name>E*TRADE FINANCIAL CORPORATION</name>
<address>
<com:street1>3 EDISON DRIVE</com:street1>
<com:city>ALPHARETTA</com:city>
<com:stateOrCountry>GA</com:stateOrCountry>
<com:zipCode>30005</com:zipCode>
</address>
</brokerOrMarketmakerDetails>
<noOfUnitsSold>35032</noOfUnitsSold>
<aggregateMarketValue>326498.24</aggregateMarketValue>
<noOfUnitsOutstanding>758427350</noOfUnitsOutstanding>
<approxSaleDate>05/22/2023</approxSaleDate>
<securitiesExchangeName>The Nasdaq Global Ma</securitiesExchangeName>
</securitiesInformation>
<securitiesToBeSold>
<securitiesClassTitle>Common Shares</securitiesClassTitle>
<acquiredDate>05/20/2023</acquiredDate>
<natureOfAcquisitionTransaction>Restricted Stock Units granted under the Roivant Sciences Ltd. Amended and Restated 2015 Equity Incentive Plan</natureOfAcquisitionTransaction>
<nameOfPersonfromWhomAcquired>Roivant Sciences Ltd.</nameOfPersonfromWhomAcquired>
<isGiftTransaction>N</isGiftTransaction>
<amountOfSecuritiesAcquired>35032</amountOfSecuritiesAcquired>
<paymentDate>05/22/2023</paymentDate>
<natureOfPayment>N/A</natureOfPayment>
</securitiesToBeSold>
<nothingToReportFlagOnSecuritiesSoldInPast3Months>N</nothingToReportFlagOnSecuritiesSoldInPast3Months>
<securitiesSoldInPast3Months>
<sellerDetails>
<name>Matthew Gline</name>
<address>
<com:street1>c/o Roivant Sciences Ltd.</com:street1>
<com:street2>7th Floor, 50 Broadway</com:street2>
<com:city>London</com:city>
<com:stateOrCountry>X0</com:stateOrCountry>
<com:zipCode>SW1H 0DB</com:zipCode>
</address>
</sellerDetails>
<securitiesClassTitle>Common Shares</securitiesClassTitle>
<saleDate>03/21/2023</saleDate>
<amountOfSecuritiesSold>18563</amountOfSecuritiesSold>
<grossProceeds>135509.9</grossProceeds>
</securitiesSoldInPast3Months>
<remarks>The securities included in Table I represent a maximum number of shares that may be sold to cover the reporting person's tax obligations when restricted stock units belonging to the reporting person are settled. The securities included in Table II represent shares sold to cover the reporting person's tax obligations when restricted stock units belonging to the reporting person were settled. Table II does not include shares that were "net settled" by the Issuer in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units previously granted to the reporting person. The securities reported in Tables I and II do not represent discretionary trades by the reporting person, and will be sold, or were sold, as applicable, for the limited purpose of satisfying tax withholding obligations.</remarks>
<noticeSignature>
<noticeDate>05/22/2023</noticeDate>
<planAdoptionDates>
<planAdoptionDate>02/22/2022</planAdoptionDate>
</planAdoptionDates>
<signature>/s/ Matthew Gline</signature>
</noticeSignature>
</formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
